Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026)
Immix Biopharma (IMMX) reported Free Cash Flow of -$9.9 million for Q1 2026, down 462.49% on a YoY basis from $2.7 million in Q1 2025, and up 11.93% sequentially from -$11.2 million in Q4 2025.
Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of Free Cash Flow data on file, last reported at -$9.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 462.49% year-over-year to -$9.9 million; the trailing twelve-month figure through Mar 2026 stood at -$32.8 million (down 144.61% YoY), and the FY2025 full-year result was -$24.7 million, down 56.37% from the prior year.
- Free Cash Flow rose to -$9.9 million in Q1 2026, from -$11.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$547066.0 in Q2 2022 to a low of -$11.2 million in Q4 2025.
- A 5-year average of -$4.1 million and a median of -$3.5 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 2781.24% in 2022 and jumped 57.55% in 2025, its largest moves.
- Tracing IMMX's Free Cash Flow over 5 years: stood at -$3.9 million in 2022, then soared by 31.08% to -$2.7 million in 2023, then advanced by 26.29% to -$2.0 million in 2024, then plunged by 464.44% to -$11.2 million in 2025, then climbed by 11.93% to -$9.9 million in 2026.
- Business Quant data shows IMMX's Free Cash Flow at -$9.9 million in Q1 2026, -$11.2 million in Q4 2025, and -$6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | -9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -11.19 Mn |
| Dec 31, 2025 | -11.19 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | -1.98 Mn |
| Dec 31, 2024 | -1.98 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -5.35 Mn |
| Jun 30, 2024 | -5.35 Mn |
| Mar 31, 2024 | -4.13 Mn |
| Mar 31, 2024 | -4.13 Mn |
| Dec 31, 2023 | -2.69 Mn |
| Dec 31, 2023 | -2.69 Mn |